Skip to main content
Izotropic Corporation logo

Izotropic Corporation — Investor Relations & Filings

Ticker · IZO ISIN · CA46604F1099 LEI · 529900IZ5PIVM7X6S027 CSE Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2021-09-16 AGM Information
Country CA Canada
Listing CSE IZO

About Izotropic Corporation

https://izocorp.com/

Izotropic Corporation develops and commercializes diagnostic medical devices, specializing in advanced breast cancer detection technology. Its flagship product is IzoView, a dedicated Breast CT imaging platform. IzoView utilizes high-resolution, true 3D imaging without requiring breast compression, offering superior spatial resolution compared to traditional modalities. The system is purpose-built to improve diagnostic accuracy and patient comfort, particularly targeting the 50% of women with dense breast tissue where conventional screening tools are often inadequate. Izotropic is currently advancing IzoView through pivotal clinical studies toward product launch and commercialization.

Recent filings

Filing Released Lang Actions
Form of proxy - English.pdf
AGM Information Classification · 100% confidence The document is a Form of Proxy for the Annual Meeting of Izotropic Corporation scheduled for October 8, 2021. It includes instructions for appointing proxyholders, voting on director elections, appointment of auditors, and other meeting-related matters. It is a solicitation of proxy votes for the Annual General Meeting (AGM). There is no financial data, management discussion, or report content. This document is clearly related to the AGM and is a proxy solicitation form, which falls under the category of AGM Information (AGM-R).
2021-09-16 English
News release - English.pdf
Regulatory Filings
2021-09-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Izotropic Corporation has received a Notice of Allowance for a new patent from the United States Patent and Trademark Office (USPTO). It discusses intellectual property developments, patent applications, and the company's business plans related to its breast CT imaging platform. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a corporate announcement about patent allowance, which fits best under a general regulatory or corporate announcement category rather than a financial or governance report. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a detailed financial or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2021-09-08 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a news release announcing the engagement of consultants for investor relations and social media services by Izotropic Corporation. It includes details about the agreements, stock options issued, and background information about the company and its product. There are no financial statements, regulatory certifications, voting results, or detailed financial data. The document is a corporate announcement related to investor relations activities rather than a formal financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) because it discusses issuance of stock options and engagement of financial marketing services, which relate to capital and financing activities.
2021-09-07 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm (Torys LLP) addressed to multiple Canadian securities commissions. It references a Pricing Supplement dated August 27, 2021, related to BMO AutoCallable Buffer Notes, Series 1767. The letter provides consent to the use of the law firm's name and opinions in the Pricing Supplement and confirms no misrepresentations in the information derived from their opinions. The document is short (1786 characters) and serves as a legal consent and opinion letter related to a financing instrument. It does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of a report but a legal attestation related to a financing document. This fits best under Regulatory Filings (RNS), which covers legal opinions, certifications, and miscellaneous regulatory documents that do not fit other categories.
2021-08-28 English
Annual MD&A - English.pdf
Regulatory Filings
2021-08-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.